Metformin and serious adverse effects

• Princess Alexandra Hospital, Brisbane, QLD.

---

• 1. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 854-865.
• 2. Glueck CJ, Wang P, Goldenberg N, Sieve-Smith L. Pregnancy outcomes among women with polycystic ovary syndrome treated with metformin. Hum Reprod 2002; 17: 2858-2864.
• 3. Slama G. The potential of metformin for diabetes prevention. Diabetes Metab 2003; 29: 104-111.
• 4. Hamilton J, Cummings E, Zdravkovic V, et al. Metformin as an adjunct therapy in adolescents with type 1 diabetes and insulin resistance: a randomized controlled trial. Diabetes Care 2003; 26: 138-143.
• 5. Brown JB, Pedula MS, Barzilay J, et al. Lactic acidosis rates in type 2 diabetes. Diabetes Care 1998; 21: 1659-1663.
• 6. Bailey CJ, Turner RC. Metformin. N Engl J Med 1996; 334: 574-579.
• 7. Calabrese AT, Coley KC, DaPos SV, et al. Evaluation of prescribing practices: risk of lactic acidosis with metformin therapy. Arch Intern Med 2002; 162: 434-437.
• 8. Emslie-Smith AM, Boyle DIR, Evans JMM, et al. Contraindications to metformin therapy in patients with type 2 diabetes — a population based study of adherence to prescribing guidelines. Diabet Med 2001; 18: 483-488.
• 9. Jones GC, Macklin JP, Alexander WD. Contraindications to the use of metformin. BMJ 2003; 326: 4-5.
• 10. Thomsen HS, Morcos SK. Contrast media and metformin: guidelines to diminish the risk of lactic acidosis in non-insulin-dependent diabetics after administration of contrast media. ESUR Contrast Media Safety Committee. Eur Radiol 1999; 9: 738-740.